NCT07232602 2026-03-16
MK-3475-04D
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
Clinical Trials
6 trialsNCT06764095 2026-02-12
Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial
Mayo Clinic
Phase 4 Recruiting
NCT05656235 2026-01-08
Renal Retention in High Grade Upper Tract Urothelial Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Recruiting
NCT07087860 2025-12-09
RECIPE-B1
Mayo Clinic
Phase 2 Recruiting
NCT06394570 2025-09-15
STAR-EV
University of Texas Southwestern Medical Center
Phase 1/2 Recruiting
NCT05756569 2025-07-28
Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology
Emory University
Phase 2 Recruiting